Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Alveolar Soft Part 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 108Rituximab 62Etoposide 56Methotrexate 52Cytarabine 52Peripheral Blood Stem Cell Transplantation 47Vincristine 45Filgrastim 43fludarabine phosphate 41Radiotherapy 37Mycophenolic Acid 35Doxorubicin 35Tacrolimus 33Busulfan 33Whole-Body Irradiation 32Prednisone 31Methylprednisolone 27Antilymphocyte Serum 27Dexamethasone 26Cyclosporine 26Melphalan 24merphos 20blinatumomab 20Leucovorin 20Granulocyte Colony-Stimulating Factor 16Carmustine 15fludarabine 14Ifosfamide 14Calcium Dobesilate 14CT-P10 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Burkitt Lymphoma × Prochlorperazine × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡